• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

siRNA Design to Silence the 3'UTR Region of Zika Virus.
Abstract The disease caused by the Zika virus (ZIKV) has positioned itself as one of the main public health problems in Mexico. One of the main reasons is it causes microcephaly and other birth defects. The transmission of ZIKV is through Aedes aegypti and Ae. albopictus mosquitoes, which are found in a larger space of the national territory. In addition, it can also be transmitted via blood transfusion, sexual relations, and maternal-fetal route. So far, there are no vaccines or specific treatments to deal with this infection. Currently, some new therapeutics such as small interfering RNAs (siRNAs) are able to re...
Source: Biomed Res - August 19, 2020 Category: Research Authors: Perez-Mendez M, Zárate-Segura P, Salas-Benito J, Bastida-González F Tags: Biomed Res Int Source Type: research

Dengue virus requires the unsaturated fatty acid biosynthesis pathway for its infection in the mammalian host
Publication date: May–July 2015 Source:New Horizons in Translational Medicine, Volume 2, Issues 4–5 Author(s): Rebekah C. Gullberg, Richard J. Kuhn, Rushika Perera Dengue virus (DENV) infection is a significant global health concern with over 40% of the world’s population at risk and currently no therapeutics or vaccines available. Understanding host viral interactions is key to developing novel therapeutic options. Dengue virus is a positive sense RNA virus that induces the formation of invaginations in the endoplasmic reticulum to replicate its genome. Increased phospholipid biosynthesis is key to the formatio...
Source: New Horizons in Translational Medicine - September 13, 2015 Category: Research Source Type: research

HIV-1, human interaction database: current status and new features
The ‘Human Immunodeficiency Virus Type 1 (HIV-1), Human Interaction Database’, available through the National Library of Medicine at http://www.ncbi.nlm.nih.gov/genome/viruses/retroviruses/hiv-1/interactions, serves the scientific community exploring the discovery of novel HIV vaccine candidates and therapeutic targets. Each HIV-1 human protein interaction can be retrieved without restriction by web-based downloads and ftp protocols and includes: Reference Sequence (RefSeq) protein accession numbers, National Center for Biotechnology Information Gene identification numbers, brief descriptions of the interaction...
Source: Nucleic Acids Research - January 15, 2015 Category: Research Authors: Ako-Adjei, D., Fu, W., Wallin, C., Katz, K. S., Song, G., Darji, D., Brister, J. R., Ptak, R. G., Pruitt, K. D. Tags: Database issue Source Type: research

A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry
HCV has infected an estimated 3% of the world population in whom viral infection persists for more than two third of the cases, often resulting in life-threatening complications. The standard of care (pegylated interferon alpha-2 plus ribavirin) is efficient in only 50% of treated patients, costly and has numerous side effects. In addition, viral resistance to newly developed drugs -- targeting viral protease or RNA polymerase -- has been described, but no vaccine is yet available. The difficulty in developing HCV vaccines is largely due to the broad sequence-diversity displayed by HCV, the frequent occurrence of viral mut...
Source: NIH OTT Licensing Opportunities - June 23, 2009 Category: Research Authors: ott-admin Source Type: research

A Novel Flavivirus-based System For Production Of Hepatitis C Virus (HCV): Production Of Infectious Virions And Development Of A Novel Reporter System For Studying HCV Virion Entry.
A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV EntryDescription of Technology: HCV has infected an estimated 3% of the world population in whom viral infection persists for more than two third of the cases, often resulting in life-threatening complications. The standard of care (pegylated interferon alpha-2 plus ribavirin) is efficient in only 50% of treated patients, costly and has numerous side effects. In addition, viral resistance to newly developed drugs -- targeting viral protease or RNA polymerase -- has been described, but no vacci...
Source: NIH OTT Licensing Opportunities - June 23, 2009 Category: Research Authors: ott-admin Source Type: research

Attenuated Salmonella as a Delivery System for siRNA-Based Tumor Therapy
This technology comprises live, attenuated Salmonella strains as a delivery system for small interfering double-stranded RNA (siRNA)-based tumor therapy. The inventors' data provide the first convincing evidence that Salmonella can be used for delivering plasmid-based siRNAs into tumors growing in vivo. Claimed in the related patent application are methods of inhibiting the growth or reducing the volume of solid cancer tumors using the si-RNA constructs directed against genes that promote tumor survival and cancer cell growth. The Stat3-siRNAs carried by an attenuated S. typhimurium described in the application exhibit tum...
Source: NIH OTT Licensing Opportunities - January 9, 2009 Category: Research Authors: admin Source Type: research

A Novel and Efficient Technology for Targeted Delivery of siRNA
The biological phenomenon of RNA interference (RNAi) has much promise for developing therapeutics to a variety of diseases. However, development of RNAi therapies remains mainly in preclinical stages largely because of difficulties in delivering small inhibitory RNAs (siRNA) and short hairpin RNAs (shRNA) into target cells. Although viral vector-based siRNA delivery systems have been widely used, their specificity and safety remains significant issue. Without a solution to this delivery problem, RNAi cannot fulfill its therapeutic promise. Investigators at the National Institutes of Health have developed novel compositions...
Source: NIH OTT Licensing Opportunities - January 1, 2009 Category: Research Authors: admin Source Type: research